Redefining the skin’s potential as a therapeutic vector


Patent-protected transdermal drug delivery platform using skin patches to provide slow-release medication. Has significant advantages over existing transdermal technologies, including usability with a wide variety of therapeutic substances, up to 7-days’ continuous dosing in one patch, and cost-effective manufacturing


Currently developing three products for Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS) and Diabetes based on proven, off-patent, active pharmaceutical ingredients for licensing to biopharma companies. Also started in-licensing therapeutic molecules with delivery challenges that their technology can overcome to generate high value assets that will be acquired by biopharma companies